



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكرو فيلم

# بسم الله الرحمن الرحيم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكرو فيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**MONA MAGHRABY**



# **STUDY OF ADDICTION IN COPD PATIENTS IN ABBASIYA CHEST HOSPITAL**

*Thesis*

**Submitted for Partial Fulfillment of M.D. Degree  
In Chest Diseases & TB**

*By*

**Mahmoud M. Muneer**

M.B.,B.Ch.

Faculty of Medicine - Cairo University

*Supervised by*

**Prof. Dr. Adel Mohamad Saeed**

Professor of Chest Diseases

Faculty of Medicine - Ain Shams University

**Dr. Riham Hazem Raafat**

Lecturer of Chest Diseases

Faculty of Medicine - Ain shams University

Faculty of Medicine

Ain Shams University

2021

# *Acknowledgement*

My greatest gratitude to **ALLAH** whose guidance and support were the main motive behind accomplishing this work.

I would like to express my profound gratitude and sincere appreciation to **Prof. Dr. Adel Mohamad Saeed**, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for his great help and support and gentle guidance and insistence. Without his help, this work would have never been accomplished.

I would also like to express my appreciation to **Dr. Riham M. Hazem M.Raafat**, Lecturer of Chest Diseases, Faculty of Medicine, Ain Shams University, for her continuous help, guidance and encouragement.

Last but not least I would like to express my deep thanks and gratitude to all family members for supporting me and pushing me forward all the time.

*Mahmoud M. Muneer*



## List of Contents

Title	Page
▪ List of Abbreviations.....	I
▪ List of Tables.....	III
▪ List of Figures .....	VI
▪ Introduction.....	1
▪ Aim of the Work .....	3
▪ Review of Literature .....	4
▪ Patients and Methods .....	74
▪ Results .....	81
▪ Discussion .....	98
▪ Conclusion and Recommendations .....	105
▪ Summary .....	107
▪ References.....	110
▪ Arabic Summary.....	--

## List of Abbreviations

<b>A5nAChR</b>	Alpha 5 Subunit Nicotinic Acetyl Choline Receptors
<b>Ach</b>	Acetyl Choline
<b>AOD</b>	Alcohol and Other Drug
<b>AODUD</b>	Describe Alcohol and Other Drug use Disorder
<b>B3AChR</b>	Beta 3 Subunit
<b>BOLD</b>	Burden of Obstructive Lung Disease
<b>CFTR</b>	Cystic Fibrosis Transmembrane Conductance Regulator
<b>ChAT</b>	Choline Acetyl Transferase
<b>CHRNA5</b>	Cholinergic Receptor Nicotenic Alpha 5 Subunit
<b>CHRNA4</b>	Cholinergic Receptor Nicotenic Beta 4 Subunit
<b>COPD</b>	Chronic Obstructive Pulmonary Disease
<b>DA</b>	Dopamine
<b>DALY</b>	Disability-Adjusted Life Year
<b>DNA</b>	De-oxy Ribo Nucleic Acid
<b>Dsm</b>	Diagnostic and Statistical Manual of Mental Disorders
<b>Fev1</b>	Forced Expiratory Volume at the 1 <sup>st</sup> Second
<b>fMRI</b>	Functional Magnetic Resonance Imaging
<b>FTND</b>	Fagerstrom Test for Nicotine Dependence
<b>Fvc</b>	Forced Vital Capacity
<b>GBD</b>	Global Burden disease

## List of Abbreviations

<b>GWA</b>	Genome Wide Association
<b>Laba</b>	long Acting Beta Agonist
<b>LAMA</b>	Long Acting Muscarinic Agonist
<b>mAChR</b>	Muscarinic Acetyl Choline Receptors
<b>NACHR</b>	N-Acetyl Choline Receptors
<b>NsclC</b>	Non Small Cell Lung Cancer
<b>PFC</b>	Pre Frontal cortex
<b>QoL</b>	Quality Of Life
<b>Saba</b>	Short Acting Beta Agonist
<b>SABR</b>	Stereotactic Ablative Radiation Therapy
<b>SBRT</b>	Stereotactic Body Radiation Therapy
<b>SUD</b>	Substance Use Disorder
<b>VTa</b>	Ventral Tegmental Area



## List of Tables

Table No.	Title	Page
<b>Table (1):</b>	Gold criteria for diagnosing and staging COPD.....	12
<b>Table (2):</b>	nAChR Genes (CHRNA) Variant and Association with Addiction, COPD and Lung Cancer.....	49
<b>Table (3):</b>	Nicotine Promotes Transformation of HBEpC Previously Exposed for One hr to 0.1 $\mu$ M BPDE .....	61
<b>Table (4):</b>	Interventions Able to Help Smoking Cessation in Nicotine Dependence Subjects, Under Patent.....	72
<b>Table (5):</b>	Demographic data of the study group (n=100) .....	81
<b>Table (6):</b>	Comparing Comorbidity in the study group by Chi square test (n=100).....	82
<b>Table (7):</b>	Comparing smoking grade in the study group by Chi square test (n=100) .....	83
<b>Table (8):</b>	Comparing special habits in the study group by Chi square test (n=100) .....	84
<b>Table (9):</b>	Comparing addiction behaviour in the study group by Chi square test (n=100) .....	85

## List of Tables (Continued)

Table No.	Title	Page
<b>Table (10):</b>	Comparing CAT score in the study group by Chi square test (n=100).....	86
<b>Table (11):</b>	Comparing ICU exacerbation admission in the study group by Chi square test (n=100) .....	87
<b>Table (12):</b>	Pulmonary function tests (PFT) of the study group (n=100) .....	88
<b>Table (13):</b>	Comparing addiction score in relation to body weight by ANOVA test (n=100).....	89
<b>Table (14):</b>	Comparing addiction score in relation to comorbidity by ANOVA test (n=100).....	90
<b>Table (15):</b>	Comparing addiction score in relation to smoking by ANOVA test (n=100).....	91
<b>Table (16):</b>	Comparing addiction score in relation to CAT score by ANOVA test (n=100) .....	92
<b>Table (17):</b>	Comparing addiction score in relation to ICU admission by ANOVA test (n=100).....	93
<b>Table (18):</b>	Pearson correlation between Addiction score and severity of disease in the study group .....	94

### **List of Tables (Continued)**

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
<b>Table (19):</b>	Pearson correlation between Addiction score and pulmonary functions test in the study group.....	95
<b>Table (20):</b>	Pearson correlation between Addiction score and age in the study group .....	97

## List of Figures

Figure No.	Title	Page
<b>Fig. (1):</b>	Tobacco-related cessation resources for providers.....	15
<b>Fig. (2):</b>	Smoking cessation support groups for patients and family members .....	17
<b>Fig. (3):</b>	Guidelines for the management of symptoms experienced by patients with lung cancer and COPD .....	30
<b>Fig. (4):</b>	Homomeric and heteromeric nAChR. In the presence of ligand (ACh or nicotine) the receptor open and Ca <sup>2+</sup> influx inside a cell .....	42
<b>Fig. (5):</b>	Schematic picture of the chromosome 15 region q25 containing the gene cluster CHRNA5- CHRNA3- CHRNB4 ...	42

## **INTRODUCTION**

The World Health Organization and the American Psychiatric Association use the term “substance dependence” rather than “drug addiction (*American Psycatric Association 2000*).

Drug addiction is a chronic, relapsing disorder in which compulsive drug-seeking and drug-taking behavior persists despite serious negative consequences (*Maddux and Desmond, 2000*).

Addictive substances induce pleasant states (euphoria in the initiation phase) or relieve distress. Continued use induces adaptive changes in the central nervous system that lead to tolerance, physical dependence, sensitization, craving, and relapse (*Cami and Farré, 2003*).

Substance abuse is characterized by recurrent and clinically significant adverse consequences related to the repeated use of substances, such as failing to fulfill major role obligations, use of drugs in situations in which it is physically hazardous, occurrence of substance-related legal problems, and continued drug use despite the presence of persistent or recurrent social or interpersonal problems (*Cami and Farré, 2003*).

Tolerance and physical dependence reflect physiological adaptation to the effects of a drug, whereas the remaining criteria define uncontrollable drug consumption. However, tolerance and physical dependence

## ***-Introduction-***

---

are neither necessary nor sufficient for a diagnosis of substance dependence. Substance abuse or harmful use, a less severe disorder, may result in dependence (*World Health Organization, 1992*).

Smokers with COPD are at high risk for poor health outcomes directly attributable to tobacco related conditions, including progression of lung disease and cardiovascular diseases (*Mullerova et al., 2013*).

Cannabis, commonly known as marijuana, is the most widely used illegal drug in the world. After tobacco, it is the second most widely smoked substance in the general population (*World Drug Report, 2006*).

The majority of people in both developed and developing countries who currently smoke tobacco and have also smoked marijuana (*Timberlake et al., 2007*).

The potential impact on lung health of marijuana smoke, with its wide range of toxins, is poorly understood (*Tetrault et al., 2007*).

Short-term heavy marijuana smoking among young adults can worsen lung function (*Tashkin et al 1987*).

Long term marijuana smoking has been linked to an increase in respiratory symptoms (*Simmons et al., 1997*).

## **AIM OF THE WORK**

The primary objective of this study is detection of different addiction patterns in COPD patients admitted in Abbasia Chest Hospital, and secondary objective is evaluation of the effect of substance abuse in disease course.